Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died ...

Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...

The biotech, which cut jobs following the rejection in May of its Barth syndrome therapy, claimed it has addressed the agency ...

A new wave of Alzheimer’s research suggests semaglutide, widely known for diabetes and weight loss, could also slow cognitive ...

On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” ...

The drug, which functions similar to psilocybin, scored positive enough results in a mid-stage study that Reunion is now ...

The oncology patent cliff presents a complex and urgent challenge. As blockbuster therapies approach loss of exclusivity, the ...